Research Article

Salivary Gland Dysfunction in Stroke Patients Is Associated with Increased Protein Glycoxidation and Nitrosative Stress

Mateusz Maciejczyk, Piotr Gerreth, Anna Zalewska, Katarzyna Hojan, and Karolina Gerreth

1Department of Hygiene, Epidemiology and Ergonomics, Medical University of Bialystok, 2C Adama Mickiewicza Street, 15-022 Bialystok, Poland
2Private Dental Practice, 57 Kasztelanska Street, 60-316 Poznan, Poland
3Experimental Dentistry Laboratory, Medical University of Bialystok, 24A Marii Sklodowskiej-Curie Street, 15-276 Bialystok, Poland
4Department of Rehabilitation, Greater Poland Cancer Centre, 15 Garbary Street, 61-866 Poznan, Poland
5Department of Occupational Therapy, Poznan University of Medical Sciences, Swiecickiego Street 6, 60-781 Poznan, Poland
6Department of Risk Group Dentistry, Chair of Pediatric Dentistry, Poznan University of Medical Sciences, 70 Bukowska Street, 60-812 Poznan, Poland

Correspondence should be addressed to Mateusz Maciejczyk; mat.maciejczyk@gmail.com

Received 2 November 2020; Revised 26 November 2020; Accepted 30 November 2020; Published 10 December 2020

Academic Editor: Massimo Collino

Copyright © 2020 Mateusz Maciejczyk et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1. Introduction

Stroke is a severe health problem in the modern world. It is defined as sudden, focal, vascular damage to the central nervous system confirmed by the presence of a stroke focus in neuroimaging studies or persistence of focal symptoms for more than 24 hours [1]. The most important risk factors for the disease are hypertension, heart disease, diabetes, dyslipidemia, and clotting disorders, which occur in most stroke patients [1]. Cerebrovascular accident is the third leading cause of severe long-term disability, the second dominant reason for death, and a fundamental cause of depression and dementia [2]. Although stroke has mainly vascular pathology, the disease affects both the brain vessels and the entire body. Indeed, stroke-related disorders include limb paresis, headaches, epileptic seizures, deep vein thrombosis,
or urinary tract infections. The incidence of stroke complications is high and affects 40-96% of hospitalized or rehabilitation patients [3].

A key role in stroke pathogenesis is attributed to oxidative stress (OS) [3, 4]. OS is defined as an oxidative-reductive imbalance (in favor of oxidation reactions) depending on lipid raft turnover, mitochondrial function, and cellular cross-talk in the neurovascular coupling [5, 6]. Excessive formation of reactive oxygen species (ROS) generates oxidative damage to various macromolecules (i.e., proteins, lipids, and DNA), changing several signaling pathways and promote cellular injury and death [5, 7]. In ischemic stroke, excess calcium, sodium, and ADP levels are responsible for the overproduction of mitochondrial free radicals. In contrast, in hemorrhagic stroke, ROS sources are mainly the conversion of arachidonic acid to prostanoids and degradation of hypoxanthine [8, 9]. Cerebral oxidative stress also exaggerates the inflammatory response (by induction of the NfkB signaling pathway), leading to enhanced expression of cytokines, chemokines, and growth factors [10]. However, nitric oxide (NO) also plays a vital role in stroke complications. It cytotoxically damages the DNA, blocks the mitochondrial function, and intensifies free radical damage by peroxynitrite formation [11].

In our previous study, we showed that in stroke patients, enhanced OS occurs not only in the blood but also in saliva [12]. Disturbances of enzymatic and nonenzymatic antioxidant barrier and increased oxidative damage to salivary lipids were noted in both nonstimulated (NWS) and stimulated whole saliva (SWS) of stroke cases. In these patients, oral hygiene and periodontal conditions are also markedly worse than age- and gender-matched healthy control [13]. This condition predisposes to other oral diseases such as burning mouth syndrome, xerostomia (subjective dry mouth), or fungal infections [14]. Nevertheless, it is still unknown whether stroke patients suffer from OS-mediated hyposalivation. This hypothesis is likely since oxidative stress is the primary factor damaging the salivary glands in both oral and systemic diseases [15, 16]. Indeed, protein glycoxidation products can aggregate and accumulate in the salivary glands leading to morphological changes and qualitative and quantitative disorders of saliva secretion [17-19]. However, of all cellular biomolecules, proteins are believed to be the primary target of ROS attack [20]. Oxidizing agents are responsible for the oxidation of single amino acid residues or entire polypeptide chains and the formation of cross-linking and tearing of the protein chain. Interestingly, oxidatively modified proteins reduce or lose their biological activity and inhibit the mechanisms responsible for their degradation [21]. Nevertheless, reduced NO bioavailability (in the secretory cells of the salivary glands) may also result in abnormalities in the protein secretion into saliva [22]. OS-mediated salivary hypofunction has been demonstrated in patients with obesity [23, 24], hypertension [22], chronic kidney disease [16], chronic heart failure [25], psoriasis [26], but also neurodegenerative diseases such as dementia and Alzheimer’s disease [27, 28]. Thus, OS could be a common denominator for central (brain) and local (salivary glands) complications in stroke patients.

Our study is aimed at assessing the relationship between salivary gland function/protein secretion into saliva and protein glycoxidation and nitrosative damage. The content of glycation and protein oxidation products and nitrosative stress was evaluated in NWS and SWS of stroke patients with normal salivary secretion and hyposalivation.

2. Material and Methods

2.1. Ethical Issues and Patient’s Consent. Before the study, it was approved by the Bioethics Committee of the Poznan University of Medical Sciences (resolutions 59/19 and 890/19).

All participants, i.e., stroke patients and healthy controls, were provided with information concerning the research’s purpose, procedures, benefits, and risks. Full written consent was obtained from all patients in accordance with the Declaration of Helsinki for dental examination and sampling of saliva.

2.2. Study Subjects. The study was performed between June and September 2019 in a health center (Boronifraterskie Centrum Zdrowia) in Piaski–Marysin (Piaski, Poland). The health center hospitalizes patients with various disorders, including those after cerebral stroke, from different country provinces. The participation of each individual in the study was voluntary. One experienced neurorehabilitation specialist qualified all the individuals for the study according to its criteria.

The study group consisted of stroke patients in the subacute phase who were emerged out of 385 individuals that were subjects in the neurorehabilitation ward following different incidents, such as spinal cord injury, brain injury, vascular brain damage, surgically treated patients with a brain tumor, myelopathy, polyneuropathy, and sclerosis multiplex. It was established that 253 (65.71%) patients were stroke survivors. They were admitted to the neurorehabilitation unit directly from the hospital, in a subacute stroke phase, immediately after the acute phase cessation. Most individuals were able to communicate, cooperate, and understand instructions. A medical doctor assessed each patient, and subsequently, he/she was subjected to comprehensive individual and similar rehabilitation. Moreover, most individuals followed the same diet divided into a baseline diet for most people or a diet for diabetes mellitus patients. All the meals were distributed to the patients at the same time daily and were prepared in this hospital.

Data concerning the condition and general health status of individuals were obtained from patients’ files and contained: age, gender, time since diagnosis of cerebral stroke, medical history, and medication used.

In addition, for measurement of the functional status of the patient, the following scales were utilized:

1. Addenbrooke’s Cognitive Examination III (ACE III)—to differentiate individuals without and with cognitive impairment [29]

2. The Berg Balance Scale (BBS) for determining an individual’s inability or ability to safely balance during a series of predetermined tasks [30]
the study were as follows: con
fi
: 0.2 mL/min was considered as hyposalivation [16, 22, 33].

Finally, 30 (11.86% of stroke survivors; 7.79% of all reha-
bilitated patients at the health center) fully completed the
examination and were considered in the analysis (Table 1).
The other individuals were excluded since, as many as 48
(12.47%) people were uncooperative because they could not
communicate and give conscious written informed consent
for participation in the research. Additionally, 117 (30.39%)
individuals declined to participate in the study, and 34
(8.83%) patients did not come for examination and saliva
sampling, even though they gave informed consent and were
reminded 3–4 times. Additionally, 14 (3.64%) subjects
resigned from the research after sampling of nonstimulated
saliva due to physiological or psychological tiredness, 7
(1.82%) people were unable to sample the saliva because of
general difficulties in understanding the procedure due to
cognitive and language deficits, and 3 (0.78%) patients were
taken to the other hospital because of deterioration of general
health.

Patients from the study group (n = 30) were divided into
two subgroups considering the rate of salivary secretion:
NS—normal salivary secretion (n = 16), HS—reduced sali-
vary secretion (hyposalivation; n = 14). NWS flow below
0.2 mL/min was considered as hyposalivation [16, 22, 33].
All participants from the control group (n = 30) had NWS
flow > 0.2 mL/min.

2.3. Study Criteria. The inclusion criteria of stroke patients to
the study were as follows: confirmed cerebral infarction or
cebral hemorrhage based on CT and magnetic resonance
imaging (MRI); recovery from the acute phase of ischemic
or hemorrhagic stroke in all brain areas; good general con-
dition; consciousness and giving of written and informed con-
sent for saliva sampling and oral examination; the age of
consent (>18 years); first admission to cure stroke unit was
more than 5–6 (to 10) hours from the onset of the early neu-
rological symptoms; adequate capacity to follow instructions,
i.e., being able to answer questions during the examination,
understanding how to perform the procedures and ability
to collect a saliva sample.

The exclusion criteria of subjects from the research were as
follows: unconfirmed cerebral infarction or cerebral hemor-
rhage with CT and magnetic resonance imaging (MRI); stroke
recurrence during subacute phase; poor general condition;
unconsciousness and inability to give informed consent for
saliva sampling and oral check-up; insufficient cooperation
due to cognitive/language deficits; incapability to collect saliva
sample; patients under the age of 18; legal guardianship; ische-
mic stroke treated with thrombectomy or thrombolysis;
patients with psychiatric or cognitive disorders; lung disease
(chronic obstructive pulmonary disease) or cardiovascular dis-
ase (angina or uncontrolled hypertension); autoimmune dis-
ase (rheumatoid arthritis, systemic lupus erythematosus);
heart failure resting oxygen saturation (SaO₂) ≤ 92%; women
suffering from malnutrition, i.e., having body mass index
lower than 18 kg/m² or with weight loss over 10% during the
previous three months. In addition, individuals taking dietary
supplements and vitamins for the last three months and
smokers were excluded from the research.

2.4. Control Group. The control group contained 30 individ-
uals similar to the study group regarding gender and age,
comorbidities, dentition and periodontium status, and oral
hygiene (Table 1). Controls included patients reporting for
dental check-up to the Department of Restorative Dentistry
of the Medical University of Białystok (Białystok, Poland)
between March and September 2017. All individuals were
provided with medical clearance by clinicians before involve-
ment in the study. Subjects followed a regular, balanced diet
(not restricted), and they were given standard physical activ-
dy recommendations.

2.5. Saliva Sampling. The sampling of saliva was carried out
in the health center during summer time, i.e., between June
and September, to keep similar weather conditions outside.

The research material was total mixed nonstimulated
saliva (NWS) and stimulated saliva (SWS), and both types
of these oral bioliquid samples were collected via spitting.
The saliva was collected between 7:30 a.m. and 9:00 a.m.
from patients who had restrained from intensive physical
activity for the preceding twelve hours. Subjects were
instructed not to intake any liquid and/or solid food other
than clean water at least two hours before sampling of saliva.
The individuals were also indicated not to perform any oral
hygiene practices (i.e., teeth brushing, gum chewing, and
mouth rinsing). Because all patients were in the subacute
phase of stroke, they had to take medicines approximately
eight hours before saliva sampling, but the time from the last
dose of any medication was minimally two hours. The con-
trols had not taken any medication eight hours before saliva
sampling [27]. The saliva was gathered in a separate, private
room after a five-minute adaptation to the environment.
Before this oral bioliquid was collected, the oral cavity was
rinsed two times with distilled water at room temperature
to avoid possible contamination from other sources. During
the study, the individuals tried to limit their face and lips'
movements, and they were seated in an adjustable chair, indi-
vidually adapted to the height of each patient, with the head
slightly bent downwards and resting in a convenient position.
The saliva samples which were gathered during the first min-
ute were ejected. Saliva was collected into a sterile Falcon tube
situated in a container with ice (temperature of approxi-
mately 0°C). The nonstimulated saliva was gathered for 10
minutes to avoid the patients’ physiological and/or psycho-
logical tiredness, whereas SWS was collected in the same
manner for 5 minutes. The saliva secretion was stimulated
by the use of 10 μL of 2% citric acid on the central part of
the tongue every 30 seconds [12, 33–36]. Subsequently, after
saliva sampling, this oral bioliquid volume was measured
using a calibrated pipette with an accuracy of 0.1 mL [34].
The minute flow of nonstimulated and stimulated saliva
was evaluated by dividing the bioliquid volume by the time
necessary for its secretion and expressed in mL/min. Instantly, after sampling of saliva, it was centrifuged (+4°C, 20 min, 3000 × g; MPW 351, MPW Med. Instruments, Warsaw, Poland). Butylated hydroxytoluene (BHT, Sigma-Aldrich, Saint Louis, MO, USA) was added to the acquired supernatants, in the amount of 10 μL 0.5 M BHT in acetonitrile (ACN)/1 mL of saliva, to protect the samples from oxidation processes [37]. The saliva samples were frozen at −80°C and stored for no more than three months for subsequent analysis.

### 2.6. Oral Examination.

The dental examination was carried out in a separate room, shortly after saliva sampling. According to the World Health Organization criteria, the dentition was evaluated in artificial lighting, using a plane mouth mirror and a dental probe [38]. The patient’s check-up was performed while seated in a chair with his/her head resting against the wall and with the dentist positioned in front of the chair. Each tooth was evaluated and scored as healthy, decayed (DT), extracted because of the carious process (MT), or filled due to caries (FT). The data gathered were utilized to calculate the DMFT index, which is the sum of DT, MT, and FT, and it expresses dental caries experience. The prevalence of dental caries was calculated as a percentage of patients with DMFT > 0. Plaque index (PII) and Gingival index (GI) were also determined on the teeth 16, 12, 24, 36, and 44.

### Table 1: Characteristics of both groups of stroke patients and controls.

| Clinical characteristics | Control group *n = 30* | Study group *n = 30* | *p value* | *NS vs. CG* | *HP vs. CG* | *NS vs. HP* |
|--------------------------|------------------------|----------------------|-----------|-------------|-------------|-------------|
| Sex                      | Male n (%)             | 19 (63.33)           | 11 (68.75)| 7 (50.00)   | ns          |             |
|                          | Female n (%)           | 11 (36.67)           | 5 (31.25) | 7 (50.00)   |             |             |
| Age in years             | (mean ± SD)            | 62.47 ± 10.43        | 63.44 ± 7.74 | 61.36 ± 13.08 | ns          |             |
| Place of residence       | Urban Center n (%)     | 10 (33.33)           | 6 (37.5)  | 2 (14.28)   |             |             |
|                          | Small town n (%)       | 9 (30.00)            | 4 (25.00) | 7 (50.00)   |             |             |
|                          | Rural area or small    | 11 (36.67)           | 6 (37.5)  | 5 (35.71)   |             |             |
| Household member(s)      | With family member n (%) | 18 (60.00)        | 11 (68.75)| 10 (71.43)  | ns          |             |
|                          | None n (%)             | 12 (40.00)           | 5 (31.25) | 4 (28.57)   |             |             |
|                          | Primary n (%)          | 3 (10.00)            | 2 (12.5)  | 1 (7.14)    |             |             |
|                          | Vocational n (%)       | 12 (40.00)           | 5 (31.25) | 7 (50.00)   |             |             |
|                          | Secondary n (%)        | 7 (23.33)            | 3 (18.75) | 4 (28.57)   |             |             |
|                          | University n (%)       | 8 (26.67)            | 6 (37.5)  | 2 (14.28)   |             |             |
|                          | Hypertension n (%)     | 21 (70.00)           | 13 (81.25)| 9 (64.29)   |             |             |
|                          | Diabetes n (%)         | 8 (26.67)            | 4 (25.00) | 4 (28.57)   |             |             |
|                          | Epilepsy n (%)         | 4 (13.33)            | 2 (12.5)  | 1 (7.14)    |             |             |
| Systemic diseases        | Arteriosclerosis n (%) | 7 (23.33)            | 3 (18.75) | 4 (28.57)   | ns          |             |
|                          | Gout n (%)             | 1 (3.33)             | 1 (6.25)  | 1 (7.14)    |             |             |
|                          | Limb thrombosis n (%)  | 2 (6.67)             | 2 (12.5)  | 0 (0.00)    |             |             |
|                          | Atrial fibrillation n (%) | 3 (10.00)      | 1 (6.25)  | 3 (21.43)   |             |             |
|                          | <5 drugs/day n (%)     | 10 (33.33)           | 7 (43.75) | 5 (35.71)   |             |             |
|                          | ≥5 drugs/day n (%)     | 20 (66.67)           | 9 (56.25) | 9 (64.29)   |             |             |
| Medications              | Hemorrhagic n (%)      | —                   | 3 (18.75) | 3 (21.43)   |             |             |
|                          | Ischemic n (%)         | —                   | 13 (81.25)| 10 (71.43)  | ns          |             |
| Type of stroke           | Ischemic → hemorrhagic n (%) | —                 | 0 (0.00)  | 1 (7.14)    |             |             |
| Numbers of strokes in the patient’s life | 1                      | —                 | 13 (81.25) | 13 (92.86)  | ns          |             |
|                          | 2                      | —                 | 3 (18.75) | 1 (7.14)    |             |             |
| Cognitive and physical functional status | ACE III (mean ± SD) | 97.27 ± 1.44        | 66.19 ± 27.03 | 72.93 ± 14.24 | <0.0001 | <0.0001 | ns |
|                          | BI (mean ± SD)         | 20.00 ± 0.00        | 11.00 ± 4.21 | 10.57 ± 3.23 | <0.0001 | <0.0001 | ns |
|                          | FIM (mean ± SD)        | 125.2 ± 0.71        | 87.44 ± 33.51 | 82.50 ± 29.22 | <0.0001 | <0.0001 | ns |
|                          | BBS (mean ± SD)        | 55.53 ± 0.51        | 33.25 ± 15.91 | 27.64 ± 17.07 | <0.0001 | <0.0001 | ns |

Abbreviations: NS: normal salivary secretion; HP: reduced salivary secretion; ns: not significant; n: number of patients; CG: control group; ACE III: Addenbrooke’s Cognitive Examination; BI: Barthel Index; FIM: functional independence measure; BBS: Berg Balance Scale; nd: no data; differences statistically significant at *p < 0.05; **p < 0.005; ***p < 0.0005; ****p < 0.0001.
2.10. Protein Glycoxidation. The concentration of salivary glycoxidation and nitrosative stress assays were performed in duplicate samples. The absorbance/fluorescence was measured using Infinite M200 PRO Multimode Microplate Reader (Tecan Group Ltd., Männedorf, Switzerland). The results were standardized to 1 mg of total protein (TP).

TP content was analyzed using a commercial kit (Thermo Scientific PIERCE BCA Protein Assay; Rockford, IL, USA), according to the manufacturer’s instructions. The saliva amylase activity was determined colorimetrically using 3,5-dinitrosalicylic acid (POCH, Gliwice, Poland) as a substrate reaction [40]. The absorbance was measured at 540 nm.

2.8. Protein Glycation. The formation of salivary Amadori products was determined using nitro blue tetrazolium (NBT) assay [41]. The absorbance of samples was measured at 525 nm. The extinction coefficient of 12 640 cm\(^{-1}\) mol\(^{-1}\) l was used for calculations.

The content of salivary advanced glycation end products (AGE) was analyzed fluorimetrically at 350/440 nm [42]. Immediately before determination, saliva samples were diluted in 0.1 M H\(_2\)SO\(_4\) (1:5, v/v) [27]. The characteristic fluorescence of pyrrole, pentosidine, furyl-furanyl-imidazole (FFI), and carboxymethyl lysine (CML) was measured in 96-well black-bottom microplates.

2.9. Protein Oxidation. The concentration of salivary protein carbonyls (PC) was determined colorimetrically based on the reaction with 2,4-dinitrophenylhydrazine (2,4-DNPH) [43]. The absorbance was measured at 355 nm. The absorption coefficient of 22 000 cm\(^{-1}\) mol\(^{-1}\) l was used for calculations.

The concentration of total thiols was determined using Ellman’s reagent [44]. The absorbance of samples was measured at 420 nm, and the concentration of total thiols was calculated from the calibration curve using reduced glutathione.

2.10. Protein Glycoxidation. The fluorescence assessment of salivary glycoxidative damage was also done. For this purpose, dityrosine, kynurenine, N-formylkynurenine, and tryptophan contents were measured fluorimetrically. The characteristic fluorescence at 330/415, 365/480, 325/434, and 295/340 nm, respectively, was measured in 96-well black-bottom microplates [45]. Immediately before determination, saliva samples were diluted in 0.1 M H\(_2\)SO\(_4\) (1:5, v/v) [27]. The results were expressed in arbitrary fluorescence units (AFU)/mg protein.

2.11. Nitrosative Stress. The concentration of salivary nitric oxide (NO) was determined colorimetrically using sulfanilamide and N-(1-naphthyl)-ethylenediamine dihydrochloride [46, 47]. The absorbance was measured at 490 nm.

The salivary peroxynitrite concentration was determined colorimetrically based on peroxynitrite-mediated nitration resulting in nitrophenol formation [48]. The absorbance was measured at 320 nm.

The concentration of salivary nitrotyrosine was determined using ELISA commercial kit (Immundiagnostik AG; Bensheim, Germany), according to the manufacturer’s instructions.

2.12. Statistics. GraphPad Prism 8.3.0 (GraphPad Software, Inc. La Jolla, USA) and Microsoft Excel 16.16.22 for macOS were used for statistical analysis. The distribution of results was assessed using the Shapiro–Wilk test, while homogeneity of variance using Levene’s test. ANOVA analysis of variance and Tukey’s HSD post hoc test were used for comparison of quantitative variables. ANOVA Kruskal–Wallis test and Dunn’s post hoc test were used if the results’ distribution was not normal. Multiplicity adjusted p value was also calculated. The nominal values were compared using the chi-square independence test. Correlations between salivary biomarkers were assessed using the Pearson correlation coefficient. The p value (two-tailed) was established as 0.05.

The number of patients was calculated a priori based on our preliminary study. Assuming the test power of 0.9 and p < 0.05, the minimum number of patients was 22 for each group (control and study). ClinCalc online calculator was used for the calculations.

3. Results

3.1. Clinical Characteristic. Sixteen stroke patients with normal salivary secretion, aged between 34 and 67 years, and fourteen individuals after stroke with hyposalivation, aged from 52 to 84 years, were recruited to the research. All subjects were in the subacute phase of cerebral stroke. The procedures, including oral examination and saliva sampling, were performed between 45 and 50 days following the stroke incident (on average 46.78 days; SD = 4.71). Table 1 presents detailed characteristics of both study groups and controls, with findings concerning demographic variables and habits of individuals.

3.2. Oral Health Status. Both groups of stroke patients presented the highest caries prevalence that amounted to 100.00%, which means none of the patients had DMFT = 0. The mean DMFT index in individuals with normal salivary secretion was lower than in persons with reduced salivary secretion (Table 2). In both groups of stroke patients, DMFT mainly depended on the number of missing teeth; however, individuals with HP had a much higher number of lost teeth than subjects with NS. In the stroke group with NS, only three individuals did not have active carious lesions (DT = 0), whereas in those with HP 9 subjects, while six patients were edentulous.
Both PI and GI were higher in stroke patients with normal salivary secretion than in those with hyposalivation.

3.3. Salivary Gland Function. NWS’s salivary flow was significantly higher in patients with stroke and normal salivary secretion than controls, while significantly lower in patients with stroke and hyposalivation. NWS’s total protein content was considerably lower in patients with stroke and decreased salivary secretion than controls and stroke patients with normal salivation. The salivary amylase activity in NWS was significantly lower in both groups of stroke patients than controls and patients with stroke with hyposalivation compared to normal salivary output (Figure 1).

The stimulated salivary flow was significantly lower in patients with stroke and decreased salivary secretion than controls and patients with normal salivary function. Similarly, total protein content and salivary amylase activity in SWS were significantly lower in patients with stroke and decreased salivary secretion than controls and stroke patients with normal salivary function (Figure 1).

3.4. Protein Glycation. The content of Amadori products was significantly higher in NWS for patients with stroke and reduced salivary secretion compared to patients with normal salivary flow and control. In SWS, Amadori products were significantly higher in the stroke HP group compared to the control (Figure 2).

In both nonstimulated and stimulated saliva in patients with stroke and reduced salivary secretion, the AGE content was significantly higher than patients with normal salivary flow and control (Figure 2).

3.5. Protein Oxidation. PC concentration was significantly higher in NWS of stroke patients with hyposalivation than

| Dental characteristics | Control group | Study group (n = 30) | p value |
|-------------------------|--------------|----------------------|---------|
| DMFT (mean ± SD)        |              |                      |         |
| Stroke with NS          | 24.90 ± 7.60 | 22.63 ± 9.67         | ns      |
| Stroke with HP          | 23.71 ± 3.31 | 23.71 ± 3.31         | ns      |
| GI (in stroke patients with HP six completely edentulous patients were excluded from calculations, i.e., n = 8) (mean ± SD) | 0.74 ± 0.79 | 0.87 ± 0.75         | ns      |
| PI (in stroke patients with HP six completely edentulous patients were excluded from calculations, i.e., n = 8) (mean ± SD) | 1.28 ± 1.01 | 1.40 ± 0.93         | ns      |

Abbreviations: NS: normal salivary secretion; HP: reduced salivary secretion; ns: not significant; n: number of patients; CG: control group; DMFT index: a sum of decayed teeth (DT), teeth missing due to carious process (MT), and teeth filled because of caries (FT); GI: Gingival Index; PI: Plaque Index.

**Table 2: Dental characteristics of both groups of stroke patients and controls.**

**Figure 1:** Salivary gland function in stroke patients and healthy controls. NS: stroke patients with normal salivary secretion; HP: stroke patients with reduced salivary secretion; NWS: nonstimulated whole saliva; SWS: stimulated whole saliva; TP: total protein concentration; ns: not significant. Differences statistically significant at *p < 0.05; **p < 0.005; ***p < 0.0005; ****p < 0.0001.
controls, while in SWS, it did not differ between all groups (Figure 3).

In both NWS and SWS, the total thiols concentration was significantly lower in both groups of stroke patients than in controls (Figure 3).

3.6. Protein Glycoxidation. The fluorescence of oxidatively-modified amino acids was shown in Figure 4.

Dityrosine fluorescence was significantly higher in the NWS of patients with stroke and hyposalivation compared to normal salivary secretion and control. In SWS, we did not show any statistical differences between the groups.

The fluorescence of kynurenine and N-formylkynurenine was significantly higher in NWS of stroke patients with hyposalivation than other groups. We found no significant differences in SWS.

Fluorescence of tryptophan was significantly lower in NWS and SWS of stroke patients with hyposalivation than controls and in NWS compared to stroke patients with normal salivary secretion.

3.7. Nitrosative Stress. Salivary nitrosative stress was presented in Figure 5.

NO concentration was significantly lower in the group of stroke patients with hyposalivation compared to other groups. However, no differences in NO concentration in SWS were found.

The peroxynitrite content was significantly higher in NWS of both stroke groups compared to the control. In SWS, the ONOO⁻ content was considerably higher in patients with stroke and hyposalivation than stroke patients with normal salivary secretion and controls.

Nitrotyrosine concentration was significantly higher in patients with stroke and hyposalivation than patients with normal salivary secretion and control but did not differ considerably in SWS.

3.8. Comparison of NWS and SWS. In general, the content of glycoxidation products and nitrosative stress biomarkers was significantly higher in NWS compared to SWS in both control and stroke patients. However, total thiols were statistically higher in stimulated saliva compared to NWS. Interestingly, in stroke patients, Amadori products' concentration was significantly higher in NWS than SWS, and such changes were not observed in control (Table 3).

3.9. Correlations. In stroke patients, the content of glycoxidation products (Amadori products, AGE, PC, dityrosine, kynurenine, and N-formylkynurenine) in NWS correlated remarkably negatively with salivary flow rate, as did the concentration of selected nitrosative stress biomarkers (NO and nitrotyrosine). However, the content of total thiols correlated positively with the NWS flow. Such changes were not observed in SWS of stroke patients (except for dityrosine and N-formylkynurenine) as well as in NWS and SWS of healthy subjects (Table 4).
Figure 4: Glycoxidation products in stroke patients and healthy controls. NS: stroke patients with normal salivary secretion; HP: stroke patients with reduced salivary secretion; NWS: nonstimulated whole saliva; SWS: stimulated whole saliva; ns: not significant. Differences statistically significant at *p < 0.05; **p < 0.005; ***p < 0.0001.

Figure 5: Nitrosative stress in stroke patients and healthy controls. NO: nitric oxide; NS: stroke patients with normal salivary secretion; HP: stroke patients with reduced salivary secretion; NWS: nonstimulated whole saliva; SWS: stimulated whole saliva; ns: not significant. Differences statistically significant at *p < 0.05; **p < 0.005; ***p < 0.0001.
Table 3: Comparison between NWS and SWS in healthy controls and stroke patients.

| Parameter                        | Control NWS | Control SWS | p value | Stroke NS NWS | Stroke NS SWS | p value | NWS Stroke HP NWS Stroke HP SWS | p value |
|----------------------------------|-------------|-------------|---------|---------------|---------------|---------|---------------------------------|---------|
| Amadori products (μmol/mg protein) | 7.21 ± 1.69 | 7.89 ± 1.99 | 0.16    | 11.01 ± 2.6   | 8.89 ± 1.9    | 0.01    |18.45 ± 4.7                      | 9.96 ± 2.3 | <0.0001 |
| AGE (AFU/mg protein)             | 332.4 ± 70.75 | 259.1 ± 115 | 0.004   | 328.3 ± 60    | 324.8 ± 75    | 0.88    | 462 ± 113                       | 432.3 ± 104 | 0.47   |
| PC (nmol/mg protein)             | 6.55 ± 1.72  | 5.93 ± 1.41  | 0.13    | 7.98 ± 2.3    | 6.49 ± 2      | 0.06    | 8.70 ± 2                        | 6.97 ± 2.1  | 0.04   |
| Thiol groups (μg/mg protein)     | 5.72 ± 1.13  | 8.27 ± 1.90  | <0.0001 | 3.86 ± 1      | 6.50 ± 2.3    | 0.0002  | 3.34 ± 0.96                     | 4.96 ± 0.99 | 0.0002 |
| Dityrosine (AFU/mg protein)      | 2.19 ± 0.67  | 1.57 ± 0.45  | <0.0001 | 2.23 ± 0.72   | 1.71 ± 0.60   | 0.03    | 2.85 ± 0.40                     | 1.78 ± 0.42 | <0.0001 |
| Kynurenine (AFU/mg protein)      | 0.56 ± 0.16  | 0.64 ± 0.18  | 0.093   | 0.72 ± 0.23   | 0.68 ± 0.2    | 0.56    | 0.77 ± 0.33                     | 0.69 ± 0.15 | 0.39   |
| N-formylkynurenine (AFU/mg protein) | 0.23 ± 0.07 | 0.32 ± 0.13  | 0.001   | 0.24 ± 0.1    | 0.36 ± 0.09   | 0.002   | 0.31 ± 0.1                      | 0.45 ± 0.1  | 0.002  |
| Tryptophan (AFU/mg protein)      | 5.05 ± 2.13  | 4.76 ± 1.47  | 0.55    | 2.57 ± 1      | 3.82 ± 1.1    | 0.002   | 2.50 ± 1.2                      | 2.88 ± 1    | 0.39   |
| NO (ng/mg protein)               | 269.3 ± 69.97| 217.3 ± 62.4 | 0.004   | 280.7 ± 79    | 204.6 ± 62    | 0.005   | 185.5 ± 123                     | 179.7 ± 96  | 0.89   |
| Peroxynitrite (nmol/mg protein)  | 66.76 ± 14.84| 50.12 ± 6.02 | <0.0001 | 105 ± 20      | 50.72 ± 12    | <0.0001 | 97.79 ± 24                      | 58.74 ± 6.5 | <0.0001 |
| Nitrotyrosine (pmol/mg protein)  | 2825 ± 267.4 | 2293 ± 258.3 | <0.0001 | 2783 ± 501    | 2509 ± 631    | 0.18    | 3220 ± 488                      | 2529 ± 559  | 0.002  |

Abbreviations: NS: normal salivary secretion; HP: reduced salivary secretion; NWS: nonstimulated whole saliva; SWS: stimulated whole saliva; AGE: advanced glycation end products; PC: protein carbonyls; NO: nitric oxide.
We did not show any significant correlations between salivary redox biomarkers and clinical parameters (data not shown).

4. Discussion

Saliva secretion is a reflex process. The reflex arch consists of afferent signals from sensory receptors in the oral cavity and is transmitted to the salivary nuclei in the medulla oblongata [49, 50]. However, in addition to afferent stimuli, the salivary nuclei also receive impulses from other brain centers. As a result, various neurotransmitters are released, which have a stimulating or inhibitory effect on salivary production [49–51]. Thus, in diseases of the central nervous system (CNS), salivary glands hypofunction and disturbances in protein secretion into saliva may occur. Since oxidative/nitrosative stress plays a crucial role in the pathogenesis of salivary gland dysfunction [12, 16, 22, 24, 52] as well as neurodegenerative diseases (including stroke) [4, 53, 54], we are the first to compare oxidation, glycation, and glycoxidation of proteins and nitrosative stress in stroke patients with normal salivary secretion and hyposalivation as well as with age and sex-matched control group.

The direct analysis of the formation of oxygen and nitrogen free radicals is practically impossible. Therefore, for the assessment of OS/nitrosative stress, the products of free radical interactions with cell components are most often used. They are much more durable than free radicals and provide information on the consequences of oxidative/nitrosative damage to the body [7].

We have shown increased oxidation and glycation of proteins in stroke patients with hyposalivation and enhanced nitrosative damage compared to stroke cases with normal salivary secretion and control groups. Interestingly, we found higher oxidative/nitrosative stress in nonstimulated saliva, which strongly correlates with salivary flow rate, total protein content, and salivary amylase activity. Notably, such relationships were not observed in the control groups.

Glycation is a slow physiological process that intensifies in many diseases [55]. Proteins with a high content of free amino acid groups, especially those containing lysine, are mainly glycated in vivo. Glycation is the formation of a bond between the free aldehyde group of glucose and the amino group of amino acid [55, 56]. The result is the creation of the labile Schiff base, which after a few weeks, converts into reactive Amadori products [57, 58]. Proteins that remain in the body for a longer time undergo further modifications (e.g., oxidation, dehydration, and fragmentation), resulting in the formation of advanced glycation end products (AGE) [59]. In our study, the content of protein glycation products (↑Amadori products and ↑AGE) was significantly higher in NWS of stroke patients with hyposalivation than patients with normal salivary secretion and healthy controls. However, in stimulated saliva, Amadori products, and AGE’s content in these patients were significantly higher only in relation to control. Interestingly, AGE can combine with a specific receptor on salivary gland cells’ surface, which triggers many proinflammatory signaling pathways such as NfkB, MAP-kinases, or p21RAS [16, 59]. There is an increased expression of many cytokines and chemokines under these conditions and an enhanced formation of oxygen/nitrogen free radicals [16, 24, 59]. Therefore, the glycation process is inextricably linked to the oxidation of proteins, which together are called glycoxidation. In our study, the severity of protein oxidation (↑PC and ↑total thiol) and glycoxidation (↑Dityrosine, ↑Kynurenine, ↑N-formylkynurenine, and ↑Tryptophan) was significantly higher in NWS of stroke patients with hyposalivation compared to the control group. Products of protein oxidation/glycation can aggregate and accumulate in the salivary glands, leading to impaired secretory function and thus changes in saliva composition [14, 17–19]. This hypothesis may be confirmed by strong correlations between oxidation/protein glycation products and salivary flow rate, total protein content, and salivary amylase activity. Importantly, these changes were observed only in the NWS of stroke patients. Accumulation

| Parameter                  | Control | Stroke | Control | Stroke |
|----------------------------|---------|--------|---------|--------|
| Amadori products           | 0.197   | 0.055  | 0.464   | 0.028  |
| AGE                        | 0.255   | 0.055  | 0.464   | 0.028  |
| PC                         | 0.055   | 0.014  | 0.464   | 0.028  |
| Thiol groups               | 0.119   | 0.127  | 0.464   | 0.028  |
| Dityrosine                 | 0.017   | 0.012  | 0.464   | 0.028  |
| Kynurenine                 | 0.017   | 0.012  | 0.464   | 0.028  |
| N-formylkynurenine         | 0.017   | 0.012  | 0.464   | 0.028  |
| Tryptophan                 | 0.017   | 0.012  | 0.464   | 0.028  |
| NO                         | 0.017   | 0.012  | 0.464   | 0.028  |
| Peroxynitrite              | 0.017   | 0.012  | 0.464   | 0.028  |
| Nitrotyrosine              | 0.017   | 0.012  | 0.464   | 0.028  |

Abbreviations: NS: normal salivary secretion; HP: reduced salivary secretion; NWS: nonstimulated whole saliva; SWS: stimulated whole saliva; AGE: advanced glycation end products; PC: protein carbonyls; NO: nitric oxide.
of such products as deposits may cause stiffening of the salivary glands’ blood vessels/secretory cells. Furthermore, in these conditions, extracellular matrix hypertrophy can also occur [14, 17–19, 25]. Since it is ethically impossible to collect salivary gland samples from stroke patients with hyposalivation, further studies on an animal model are necessary to confirm our hypotheses. Nevertheless, OS-mediated salivary hypofunction has been demonstrated in patients with obesity [23, 24], hypertension [22], chronic kidney disease [16], chronic heart failure [25], but also neurodegenerative diseases such as dementia or Alzheimer’s disease [27, 28]. Given that the risk factors for stroke are the abovementioned metabolic and cardiovascular diseases [1, 4], OS can lead to hypofunction of the salivary glands also in our patients.

The increase in salivary secretion in stroke patients with normosalivation (compared to control) may be surprising. However, this may suggest salivary secretion disorders at the level of extraganglionic parasympathetic and sympathetic nerves/salivary nuclei rather than at the salivary gland level [49, 50]. An increase in saliva production may also result from pharmacotherapy in the stroke’s subacute phase [60]. Although the exact mechanism is unknown, the increase in saliva production can be attributed to the stimulation of muscarinic M4 and M1 receptors or to blocking the alpha 2-adrenergic receptor [61]. It should be remembered, however, that none of our patients have been found to have hypersalivation.

Nitric oxide (NO) plays an essential role in the initiation of saliva secretion [50, 62]. Indeed, NO produced by neuronal nitric oxide synthase (nNOS) (together with methacholine and substance P) leads to increased calcium ion concentration inside the secretory cells of salivary glands. This is responsible for activating the potassium and chloride channels dependent on Ca\(^{2+}\) and starts the formation of primary saliva [16, 62]. In our study, NO concentration in NWS was significantly reduced in stroke cases with hyposalivation compared to patients with normal salivary secretion and control. This suggests an impaired initiation of salivary secretion, which ultimately leads to hyposalivation in stroke patients. Reduced bioavailability of salivary NO is undoubtedly due to increased peroxynitrite production formed from NO and superoxide radical anions. ONOO- causes nitration of aromatic amino acids such as tryptophan and tyrosine and impairs many enzymes’ functioning [63]. In our study, the content of ONOO- and 3-nitrotyrosine was significantly higher in NWS of stroke patients with hyposalivation compared to healthy controls. Their content correlates strongly negatively with salivary glands’ secretory function, indicating the role of nitrosative stress in salivary secretion impairment in stroke patients.

Saliva is produced in an amount of about 500–1000 ml per day. Without stimulation, the largest volume of saliva is produced by the submandibular glands. These salivary glands are mixed glands containing follicular cells, which secrete mucous and mucin-rich saliva. However, during stimulation, saliva is secreted mainly by the parotid salivary glands [35, 64, 65]. In contrast to NWS, the saliva produced by parotid glands is low-density, watery, and rich in α-amylase [65, 66]. In our study, increased oxidation/glycation of proteins and nitrosative stress was mainly observed in the nonstimulated saliva of stroke patients with hyposalivation. Moreover, the assessed redox biomarkers’ content was significantly higher in NWS than in SWS, suggesting that mainly the submandibular salivary gland is disturbed in stroke patients. The consequence of reduced saliva secretion may be subjective dryness of the oral mucosa (xerostomia) and an increased incidence of dental caries, periodontal diseases, and fungal infections [14, 67]. Considering that antioxidant supplementation improves the secretory function of salivary glands in various systemic diseases [19, 68–70], the administration of free radical scavengers may be considered in stroke patients. Nevertheless, further studies are needed.

Nevertheless, salivary oxidative/nitrosative stress may not only be the origin of the salivary glands. In fact, many compounds pass from plasma to saliva through passive/facilitated diffusion and active transport or are also the gingival fluid filtrate [66, 71]. Unfortunately, in our study, we did not evaluate the products of protein glycation, oxidation and glycoxidation, and nitrosative stress in stroke patients’ blood due to the lack of consent of the local ethics committee. However, we would like to point out that the evaluated redox biomarkers’ concentration correlated remarkably negatively (Amadori, AGE, PC, dityrosine, kynurenine, N-formylkynurenine, and nitrotyrosine) or positively (total thiols and ONOO-) with NWS flow rate only in stroke patients. This may indicate the involvement of OS/nitrosative protein damage in salivary gland hypofunction. The relationship between reduced salivary flow and enhanced oxidation, glycation, and nitration of proteins was observed in patients with obesity [23, 24], hypertension [22], chronic kidney disease [16, 72], and chronic heart failure [25]. Importantly, salivary oxidative stress did not correlate with changes at the central level (blood), and similar observations can be expected in stroke patients. Therefore, our study is the starting point for further clinical observations.

Many experimental and clinical studies have confirmed the contribution of OS/nitrosative stress in stroke pathology [9, 73, 74]. After cerebral damage resulting from ischemia/bleeding, posterior reperfusion occurs. Large amounts of oxygen are supplied to maintain the viability of the neurons. Nevertheless, at the same time, high ROS levels are generated, mainly in the mitochondrial respiratory chain. Since the mitochondria cannot keep up with the oxygen conversion, oxidative brain injury occurs [9, 73, 74]. The effect of ROS action is the peroxidation of membrane lipids, as well as the disturbed function of receptors, ion channels, and other cellular proteins [3, 4]. Although we have not evaluated the products of protein glycoxidation/nitration at a systemic level, it can be assumed that the common denominator of stroke complications in the brain and salivary glands may be oxidative/nitrosative stress. Unfortunately, our study does not explain why some patients with stroke develop hyposalivation, and some do not. Using correlation analysis, we did not show any relationship between demographic/clinical variables and redox status in stroke patients with hyposalivation and normal salivary secretion (data not shown). This issue undoubtedly requires further research and clinical observation, especially on a larger group of stroke patients.
It must be emphasized that the present research has some strengths. Firstly, the participants were adequately chosen from a stroke patient population and divided into two subgroups, i.e., normal and reduced salivary secretion. Secondly, two saliva samples from each individual, i.e., stimulated and unstimulated, were collected. Thirdly, saliva sampling was performed under the same conditions during the same season, and storage, handling, processing, and analysis methods were uniform. Finally, most subjects used the same diet, except for the individuals who had diabetes mellitus. Unfortunately, this study also has some limitations. We assessed only selected biomarkers of oxidative/nitrosative stress, and therefore, we could not fully characterize the redox homeostasis of stroke individuals. In addition, the redox status was determined only in saliva. Thus, in subsequent researches, it would be advisable to evaluate the saliva–blood interconnection of redox biomarkers and their diagnostic utility in much more numerous groups of subjects and including more biomarkers. Moreover, samples of saliva were collected from stroke individuals in the shortest possible time, i.e., in the disease’s early subacute phase. The gathering of material directly after the stroke and receiving informed and written consent from all individuals was impossible because of patients’ lesser or greater cognitive and physical deficits. Moreover, we could not exclude the influence of comorbidities on the assessed redox biomarkers. Finally, the impact of pharmacotherapy on the composition and secretion of saliva could not be eliminated.

5. Conclusion

In stroke patients, the function of salivary glands (mainly submandibular glands) is disturbed, and salivary protein glycoxidation/nitration is increased. Oxidative and nitrosative stress may be one of the mechanisms responsible for the impairment of saliva secretion in stroke patients. In these patients, antioxidant supplementation may be considered. However, extraglandular sources of salivary oxidative stress in stroke patients cannot be excluded. Further studies to assess salivary gland hypofunction in stroke cases are necessary.

Data Availability

The article contains complete data used to support the findings of this study.

Conflicts of Interest

The authors declare no conflict of interest.

Acknowledgments

This work was supported by grants from the Medical University of Białystok, Poland (grant numbers: SUB/1/DN/20/002/1209 and SUB/1/DN/20/002/3330). Dr. Mateusz Maciejczyk was supported by the Foundation for Polish Science (FNP).

References

[1] G. J. Hankey, “Stroke,” Lancet, vol. 389, no. 10069, pp. 641–654, 2017.
[2] W. Johnson, O. Onuma, M. Owolabi, and S. Sachdev, “Stroke: a global response is needed,” Bulletin of the World Health Organization, vol. 94, pp. 34–634A, 2016.
[3] H. Zhao, Z. Han, X. Ji, and Y. Luo, “Epigenetic regulation of oxidative stress in ischemic stroke,” Aging and Disease, vol. 7, p. 295, 2016.
[4] P. J. Crack and J. M. Taylor, “Reactive oxygen species and the modulation of stroke,” Free Radical Biology & Medicine, vol. 38, no. 11, pp. 1433–1444, 2005.
[5] R. Ye, M. Shi, Q. Liu, and J. Chen, “Redox imbalance and stroke,” Oxidative Medicine and Cellular Longevity, vol. 2016, 2 pages, 2016.
[6] E. Heropolitanska-Pliszka, K. Berk, M. Maciejczyk et al., “Systemic redox imbalance in patients with chronic granulomatous disease,” Journal of Clinical Medicine, vol. 9, no. 5, p. 1397, 2020.
[7] E. Supruniuk, M. Maciejczyk, A. Zalewska, J. Górska, and A. Chabowski, "Blood profile of cytokines, chemokines, growth factors, and redox biomarkers in response to different protocols of treadmill running in rats," International Journal of Molecular Sciences, vol. 21, no. 21, p. 8071, 2020.
[8] R. Shirle, E. N. J. Ord, and L. M. Work, "Oxidative stress and the use of antioxidants in stroke," Antioxidants, vol. 3, pp. 472–501, 2014.
[9] K. P. Doyle, R. P. Simon, and M. P. Stenzel-Poore, "Mechanisms of ischemic brain damage," Neuropharmacology, vol. 55, no. 3, pp. 310–318, 2008.
[10] M. Maciejczyk, E. Zebrowska, and A. Chabowski, "Insulin resistance and oxidative stress in the brain: what’s new?," International Journal of Molecular Sciences, vol. 20, p. 874, 2019.
[11] L. Adams, M. C. Franco, and A. G. Estevez, "Reactive nitrogen species in cellular signaling," Experimental Biology and Medicine, vol. 240, no. 6, pp. 711–717, 2015.
[12] P. Gerrith, M. Maciejczyk, A. Zalewska, K. Gerrith, and K. Hojans, "Comprehensive evaluation of the oral health status, salivary gland function, and oxidative stress in the saliva of patients with subacute phase of stroke: a case-control study," Journal of Clinical Medicine, vol. 9, no. 7, p. 2252, 2020.
[13] H. T. Kim, J. B. Park, W. C. Lee, Y. J. Kim, and Y. Lee, "Different in the oral health status and oral hygiene practices according to the extent of post-stroke sequelae," Journal of Oral Rehabilitation, vol. 45, no. 6, pp. 476–484, 2018.
[14] J. Saleh, M. A. Z. Figueiredo, K. Cherubini, and F. G. Salum, "Salivary hypofunction: an update on aetiology, diagnosis and therapeutics," Archives of Oral Biology, vol. 60, no. 2, pp. 242–255, 2015.
[15] P. Żukowski, M. Maciejczyk, and D. Waszkiew, "Sources of free radicals and oxidative stress in the oral cavity," Archives of Oral Biology, vol. 92, pp. 8–17, 2018.
[16] M. Maciejczyk, J. Szulimowska, K. Taranta-Janusz, A. Wasilewska, and A. Zalewska, "Salivary gland dysfunction, protein glycoxidation and nitrosative stress in children with chronic kidney disease," Journal of Clinical Medicine, vol. 9, p. 1285, 2020.
[17] A. Zalewska, D. Ziembicka, M. Źródzian-Piotrowska, and M. Maciejczyk, "The impact of high-fat diet on mitochondrial...
function, free radical production, and nitrosative stress in the salivary glands of Wistar rats,” Oxidative Medicine and Cellular Longevity, vol. 2019, Article ID 2606120, 15 pages, 2019.

[18] A. Zalewska, M. Maciejczyk, J. Szulimowska, M. Imierska, and A. Blachnio-Zabielska, “High-fat diet affects ceramide content, disturbs mitochondrial redox balance, and induces apoptosis in the submandibular glands of mice,” Biomolecules, vol. 9, no. 12, p. 877, 2019.

[19] A. Zalewska, I. Szarmach, M. Żendzian-Piotrowska, and M. Maciejczyk, “The effect of N-acetylcysteine on respiratory enzymes, ADP/ATP ratio, glutathione metabolism, and nitrosative stress in the salivary gland mitochondria of insulin resistant rats,” Nutrients, vol. 12, no. 2, p. 458, 2020.

[20] Z. Cai and L.-J. Yan, “Protein oxidative modifications: beneficial roles in disease and health,” Journal of Biochemical and Pharmacological Research, vol. 1, pp. 15–26, 2013.

[21] E. R. Stadtman and R. L. Levine, “Free radical-mediated oxidation of free amino acids and amino acid residues in proteins,” Amino Acids, vol. 25, pp. 207–218, 2003.

[22] M. Maciejczyk, K. Taranta-Janusz, A. Wasilewska, A. Kossakowska, and A. Zalewska, “A case-control study of salivary redox homeostasis in hypertensive children. Can salivary uric acid be a marker of hypertension?,” Journal of Clinical Medicine, vol. 9, no. 3, p. 837, 2020.

[23] M. Maciejczyk, J. Matczuk, M. Żendzian-Piotrowska et al., “Eight-week consumption of high-sucrose diet has a prooxidant effect and alters the function of the salivary glands of rats,” Nutrients, vol. 10, no. 10, p. 1530, 2018.

[24] A. Zalewska, A. Kossakowska, K. Taranta-Janusz et al., “Dysfunction of salivary glands, disturbances in salivary antioxidants and increased oxidative damage in saliva of overweight and obese adolescents,” Journal of Clinical Medicine, vol. 9, no. 2, p. 548, 2020.

[25] A. Klimiuk, A. Zalewska, R. Sawicki, M. Knapp, and M. Maciejczyk, “Salivary oxidative stress increases with the progression of chronic heart failure,” Journal of Clinical Medicine, vol. 9, p. 769, 2020.

[26] A. Skutnik-Radziszewska, M. Maciejczyk, J. Iliśiak et al., “Enhanced inflammation and nitrosative stress in the saliva and plasma of patients with plaque psoriasis,” Journal of Clinical Medicine, vol. 9, p. 745, 2020.

[27] A. Klimiuk, M. Maciejczyk, M. Choromańska, K. Fejfer, N. Waszkiewicz, and A. Zalewska, “Salivary redox biomarkers in different stages of dementia severity,” Journal of Clinical Medicine, vol. 8, p. 840, 2019.

[28] M. Maciejczyk, A. Zalewska, and K. Gerreh, “Salivary redox biomarkers in selected neurodegenerative diseases,” Journal of Clinical Medicine, vol. 9, p. 497, 2020.

[29] J. A. Mattias-Guiu, A. Cortés-Martínez, M. Valles-Salgado et al., “Addenbrooke’s cognitive examination III: diagnostic utility for mild cognitive impairment and dementia and correlation with standardized neuropsychological tests,” International Psychogeriatrics, vol. 29, no. 1, pp. 105–113, 2017.

[30] D. R. Louie and J. J. Eng, “Berg balance scale score at admission can predict walking suitable for community ambulation at discharge from inpatient stroke rehabilitation,” Journal of Rehabilitation Medicine, vol. 50, no. 1, pp. 37–44, 2018.

[31] W. Liu, J. Unick, E. Galik, and B. Resnick, “Barthel index of activities of daily living,” Nursing Research, vol. 64, no. 2, pp. 88–99, 2015.

[32] D. Chumney, K. Nollinger, K. Shesko, K. Skop, M. Spencer, and R. A. Newton, “Ability of functional independence measure to accurately predict functional outcome of stroke-specific population: systematic review,” Journal of Rehabilitation Research and Development, vol. 47, no. 1, pp. 17–29, 2010.

[33] M. Maciejczyk, A. Zalewska, and J. R. Ladny, “Salivary antioxidant barrier, redox status, and oxidative damage to proteins and lipids in healthy children, adults, and the elderly,” Oxidative Medicine and Cellular Longevity, vol. 2019, 12 pages, 2019.

[34] A. Skutnik-Radziszewska, M. Maciejczyk, K. Fejfer et al., “Salivary antioxidants and oxidative stress in psoriatic patients: can salivary Total oxidant status and oxidative status index be a plaque psoriasis biomarker?,” Oxidative Medicine and Cellular Longevity, vol. 2020, Article ID 9086024, 12 pages, 2020.

[35] F. G. Bellagambi, T. Lomonaco, P. Salvo et al., “Saliva sampling: methods and devices. An overview,” TRAC Trends in Analytical Chemistry, vol. 124, article 115781, 2020.

[36] K. Morawska, M. Maciejczyk, L. Poplawski, A. Poplawsk-Kita, A. Krętowski, and A. Zalewska, “Enhanced salivary and general oxidative stress in Hashimoto’s thyroiditis women in euthyresis,” Journal of Clinical Medicine, vol. 9, p. 2102, 2020.

[37] J. Tocewska, M. Maciejczyk, T. Konopka, and A. Zalewska, “Total oxidant and antioxidant capacity of gingival crevicular fluid and saliva in patients with periodontitis: review and clinical study,” Antioxidants, vol. 9, no. 5, p. 450, 2020.

[38] World Health Organization, Oral health surveys: basic methods, World Health Organization, 2013, ISBN 9789241548649.

[39] J. Silnes and H. Løe, “Periodontal disease in pregnancy II. Correlation between oral hygiene and periodontal condition. Acta Odontol,” Scandinavica, vol. 22, pp. 121–135, 2009.

[40] M. Maciejczyk, A. Kossakowska, J. Szulimowska et al., “Lyso-somal exoglycosidase profile and secretory function in the salivary glands of rats with streptozotocin-induced diabetes,” Journal Diabetes Research, vol. 2017, pp. 1–13, 2017.

[41] R. Johnson and J. Baker, “Assay of serum fructosamine: internal vs external standardization,” Clinical Chemistry, vol. 33, no. 10, pp. 1955–1956, 1987.

[42] M. Kalousová, T. Žima, V. Tesař, S. Dusilová-Sulková, and J. Širža, “Advanced glycoxidation end products in chronic diseases - clinical chemistry and genetic background,” Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, vol. 579, no. 1-2, pp. 37–46, 2005.

[43] A. Z. Reznick and L. Packer, “[38] Oxidative damage to proteins: spectrophotometric method for carbonyl assay,” Methods in Enzymology, vol. 233, pp. 357–363, 1994.

[44] G. L. Ellman, “Tissue sulfhydryl groups,” Archives of Biochemistry and Biophysics, vol. 82, no. 1, pp. 70–77, 1959.

[45] C. Pawlukianiec, M. E. Gryciuk, K. M. Mil, M. Żendzian-Piotrowska, A. Zalewska, and M. Maciejczyk, “A new insight into meloxicam: assessment of antioxidant and anti-glycating activity in in vitro studies,” Pharmaceuticals, vol. 13, no. 9, p. 240, 2020.

[46] M. B. Grisham, G. G. Johnson, and J. R. Lancaster, “Quantitation of nitrate and nitrite in extracellular fluids,” Methods in Enzymology, vol. 268, pp. 237–246, 1996.

[47] J. Borys, M. Maciejczyk, B. Antonowicz et al., “Glutathione metabolism, mitochondria activity, and nitrosative stress in patients treated for mandible fractures,” Journal of Clinical Medicine, vol. 127, 2019.
G. B. Proctor and G. H. Carpenter, B. Sawczuk, M. Maciejczyk, M. Sawczuk-Siemieniuk, A. Cz
G. Varga, J. S. Beckman, H. Ischiropoulos, L. Zhu et al., "Oxidative Medicine and Cellular Longevity,
G. H. Kim, J. E. Kim, S. J. Rhie, and S. Yoon, A. M. Schmidt, O. Hori, J. Brett, S. Du Yan, J. L. Wautier, and
E. Ż C. Ott, K. Jacobs, E. Haucke, A. Navarrete Santos, T. Grune, A. Lomniczi, A. M. Suburo, J. C. Elverdin et al.,
B. Alvarez and R. Radi, D. A. Froehlich, R. M. Pangborn, and J. R. Whitaker, "The effect of oral stimulation on human parotid salivary flow rate and alpha-amylase secretion," Physiology & Behavior, vol. 41, no. 3, pp. 209–217, 1987.

[48] J. S. Beckman, H. Ischiropoulos, L. Zhu et al., "Kinetics of superoxide dismutase- and iron-catalyzed nitration of phenolics by peroxynitrite," Archives of Biochemistry and Biophysics, vol. 298, no. 2, pp. 438–445, 1992.

[49] G. Varga, "Physiology of the salivary glands," Surgery, vol. 33, pp. 581–586, 2015.

[50] G. B. Proctor and G. H. Carpenter, "Regulation of salivary gland function by autonomic nerves," Autonomic Neuroscience, vol. 133, no. 1, pp. 3–18, 2007.

[51] A. M. L. Pedersen, C. E. Sørensen, G. B. Proctor, G. H. Carpenter, and J. Ekström, "Salivary secretion in health and disease," Journal of Oral Rehabilitation, vol. 45, no. 9, pp. 730–746, 2018.

[52] B. Sawczuk, M. Maciejczyk, M. Sawczuk-Siemieniuk, R. Posmyk, A. Zalewska, and H. Car, "Salivary gland function, antioxidant defence and oxidative damage in the saliva of patients with breast cancer: does the BRCA1 mutation disturb the salivary redox profile?" Cancers (Basel), vol. 11, no. 10, p. 1501, 2019.

[53] S. Gandhi and A. Y. Abramov, "Mechanism of oxidative stress in neurodegeneration," Oxidative Medicine and Cellular Longevity, vol. 2012, 11 pages, 2012.

[54] G. H. Kim, J. E. Kim, S. J. Rhie, and S. Yoon, "The role of oxidative stress in neurodegenerative diseases," Experimental Neurobiology, vol. 24, no. 4, pp. 325–340, 2015.

[55] R. A. Gomes, L. M. A. Oliveira, M. Silva et al., "Protein glycation in vivo: functional and structural effects on yeast enolase," The Biochemical Journal, vol. 416, no. 3, pp. 317–326, 2008.

[56] A. M. Schmidt, O. Hori, J. Brett, S. Du Yan, J. L. Wautier, and D. Stern, "Cellular receptors for advanced glycation end products: implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions," Arteriosclerosis and Thrombosis, vol. 14, pp. 1521–1528, 1994.

[57] E. Żebrowska, A. Chabowski, A. Zalewska, and M. Maciejczyk, "High-sugar diet disrupts hypothalamic but not cerebral cortex redox homeostasis," Nutrients, vol. 12, no. 10, p. 3181, 2020.

[58] J. Anguizola, R. Matsuda, O. S. Barnaby et al., "Review: glycation of human serum albumin," Clinica Chimica Acta, vol. 425, pp. 64–76, 2013.

[59] C. Ott, K. Jacobs, E. Haucke, A. Navarrete Santos, T. Grune, and A. Simm, "Role of advanced glycation end products in cellular signaling," Redox Biology, vol. 2, pp. 411–429, 2014.

[60] A. Czolokowska and M. Lesniak, "Pharmacotherapy in stroke rehabilitation," Expert Opinion on Pharmacotherapy, vol. 10, no. 8, pp. 1249–1259, 2009.

[61] J. Miranda-Rius, L. Brunet-Llobet, E. Lahor-Soler, and M. Farré, "Salivary secretory disorders, inducing drugs, and clinical management," International Journal of Medical Sciences, vol. 12, no. 10, pp. 811–824, 2015.

[62] A. Lomniczi, A. M. Suburo, J. C. Elverdin et al., "Role of nitric oxide in salivary secretion," Neuroimmunomodulation, vol. 5, no. 5, pp. 226–233, 1998.

[63] B. Alvarez and R. Radi, "Peroxynitrite reactivity with amino acids and proteins," Amino Acids, vol. 25, no. 3-4, pp. 305–311, 2003.

[64] D. A. Froehlich, R. M. Pangborn, and J. R. Whitaker, "The effect of oral stimulation on human parotid salivary flow rate and alpha-amylase secretion," Physiology & Behavior, vol. 41, no. 3, pp. 209–217, 1987.

[65] G. B. Proctor, "The physiology of salivary secretion," Periodontology 2000, vol. 70, no. 1, pp. 11–25, 2016.

[66] G. H. Carpenter, "The secretion, components, and properties of saliva," Annual Review of Food Science and Technology, vol. 4, no. 1, pp. 267–276, 2013.

[67] K. Károlyházy, Z. Arányi, P. Hermann, I. Vastagh, and K. Mártón, "Oral health status of stroke patients related to residual symptoms: a case-control epidemiological study in Hungary," Oral Health and Preventive Dentistry, vol. 16, 2018.

[68] P. Żukowski, M. Maciejczyk, J. Matczuk et al., "Effect of N-acetylcysteine on antioxidant defense, oxidative modification, and salivary gland function in a rat model of insulin resistance," Oxidative Medicine and Cellular Longevity, vol. 2018, 11 pages, 2018.

[69] R. J. Reiter, S. A. Rosales-Corral, X. Y. Liu, D. Acuna-Castroviejo, G. Escames, and D. X. Tan, "Melatonin in the oral cavity: physiological and pathological implications," Journal of Periodontal Research, vol. 50, no. 1, pp. 9–17, 2015.

[70] F. K. Ibuki, C. T. Bergamaschi, M. da Silva Pedrosa, and F. N. Nogueira, "Effect of vitamin C and E on oxidative stress and antioxidant system in the salivary glands of STZ-induced diabetic rats," Archives of Oral Biology, vol. 116, article 104765, 2020.

[71] M. Knaś, M. Maciejczyk, D. Waszkiel, and A. Zalewska, "Oxidative stress and salivary antioxidants," Dental and Medical Problems, vol. 50, pp. 461–466, 2013.

[72] F. N. Nogueira, A. C. Romero, M. da Silva Pedrosa, F. K. Ibuki, and C. T. Bergamaschi, "Oxidative stress and the antioxidant system in salivary glands of rats with experimental chronic kidney disease," Archives of Oral Biology, vol. 113, article 104709, 2020.

[73] A. Cherubini, C. Ruggiero, M. C. Polidori, and P. Mecocci, "Potential markers of oxidative stress in stroke," Free Radical Biology & Medicine, vol. 39, no. 7, pp. 841–852, 2005.

[74] E. Mariani, M. C. Polidori, A. Cherubini, and P. Mecocci, "Oxidative stress in brain aging, neurodegenerative and vascular diseases: an overview," Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, vol. 827, no. 1, pp. 65–75, 2005.